Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization
J Kevin Hicks, JJ Swen, A Gaedigk - Current drug metabolism, 2014 - ingentaconnect.com
The cytochrome P450 2D6 (CYP2D6) enzyme contributes to the metabolism and/or
bioactivation of approximately 25% of clinically used drugs. The CYP2D6 gene locus is …
bioactivation of approximately 25% of clinically used drugs. The CYP2D6 gene locus is …
The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to …
Objective: To compare healthcare resource utilization (HRU) and clinical decision-making
for elderly patients based on cytochrome P450 (CYP) pharmacogenetic testing and the use …
for elderly patients based on cytochrome P450 (CYP) pharmacogenetic testing and the use …
[图书][B] A dangerous master: How to keep technology from slipping beyond our control
W Wallach - 2015 - books.google.com
We live in an age of awesome technological potential. From nanotechnology to synthetic
organisms, new technologies stand to revolutionize whole domains of human experience …
organisms, new technologies stand to revolutionize whole domains of human experience …
How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping
P Verbeurgt, T Mamiya, J Oesterheld - Pharmacogenomics, 2014 - Taylor & Francis
Aim: Drug–drug interactions (DDIs) are a widely recognized major cause of adverse drug
reactions, but two other newly described important types of interactions also exist: drug …
reactions, but two other newly described important types of interactions also exist: drug …
Clinical validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes
CA Altar, JM Carhart, JD Allen, DK Hall-Flavin… - The …, 2015 - nature.com
In four previous studies, a combinatorial multigene pharmacogenomic test (GeneSight)
predicted those patients whose antidepressant treatment for major depressive disorder …
predicted those patients whose antidepressant treatment for major depressive disorder …
Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF …
MEG Naranjo, F Rodrigues-Soares… - Omics: a journal of …, 2018 - liebertpub.com
Abstract Pharmacogenetic variation in Latin Americans is understudied, which sets a barrier
for the goal of global precision medicine. The RIBEF-CEIBA Network Consortium was …
for the goal of global precision medicine. The RIBEF-CEIBA Network Consortium was …
To genotype or phenotype for personalized medicine? CYP450 drug metabolizing enzyme genotype–phenotype concordance and discordance in the Ecuadorian …
F De Andrés, S Terán, F Hernández… - Omics: a journal of …, 2016 - liebertpub.com
Genetic variations within the cytochrome P450 (CYP450) superfamily of drug metabolizing
enzymes confer substantial person-to-person and between-population differences in …
enzymes confer substantial person-to-person and between-population differences in …
Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population
F de Andrés, C Altamirano-Tinoco… - The …, 2021 - nature.com
Interethnic variability in the drug-metabolizing capacity of CYP450 enzymes may lead to
discrepancies in the relationship between genotypes and phenotypes worldwide. The …
discrepancies in the relationship between genotypes and phenotypes worldwide. The …
Length of Psychiatric Hospitalization is Correlated With CYP2D6 Functional Status in Inpatients with Major Depressive Disorder
G Ruaño, BL Szarek, D Villagra, K Gorowski… - Biomarkers in …, 2013 - Taylor & Francis
Aim: This study aimed to determine the effect of the CYP2D6 genotype on the length of
hospitalization stay for patients treated for major depressive disorder. Methods: A total of 149 …
hospitalization stay for patients treated for major depressive disorder. Methods: A total of 149 …
A one-year follow-up study of treatment-compliant suicide attempt survivors: relationship of CYP2D6-CYP2C19 and polypharmacy with suicide reattempts
EM Peñas-Lledó, S Guillaume, F de Andrés… - Translational …, 2022 - nature.com
This study of a cohort of 1-year treatment-compliant survivors of a suicide attempt examined
for the first time whether a high CYP2D6-CYP2C19 metabolic capacity (pharmacogenes …
for the first time whether a high CYP2D6-CYP2C19 metabolic capacity (pharmacogenes …